Product Pipeline


Innovative, exciting technology with extraordinary potential

Our pipeline currently centers on two promising compounds developed by world renowned Professors’ Chang and Han.

This platform drug as shown promise for the treatment of Acute Myeloid Leukemia.  Formally known as TPA, this platform small molecule has many potential therapeutic uses.  Rich Pharmaceuticals is exploring multiple indications for the highest likelihood of commercialization success that has the potential to become new compelling treatments for patients.



May 9th, 2017

Rich Pharmaceuticals’s Division CannCodex, Releases List of Conditional Use Permits Issued in California to Medicinal Cannabis Businesses
View Release

April 10th, 2017

Rich Pharmaceuticals Welcomes New Board Member
View Release

April 6th, 2017

Rich Pharmaceuticals announces Industry Veteran to Join CannCodex
View Release

» View All News

Stock Price